Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
RQ Biotechnology Ltd. in London is seeking a Principal Scientist to own antibody characterisation and screening strategy across our next-generation discovery programmes.
You will decide how antibodies are tested, interpret data, set progression criteria, and drive candidate selection with discovery, engineering, computational and virology colleagues. You will stay hands-on to troubleshoot assays and mentor scientists.
RQ Biotechnology (RQ Bio) is a UK virology biotech developing long-acting monoclonal antibodies against seasonal influenza. Our discovery engine combines computational design with experimental antibody discovery, and we are now building our next generation of programmes.
We are looking for a Principal Scientist to own antibody characterisation and screening strategy across our next-generation discovery programmes.
Antibodies flow into our screening cascade from multiple computational and discovery workstreams. You will decide how they are tested, interpret what the data is telling us, and recommend which molecules move forward. This is a scientific decision-making role: you will set progression criteria, identify liabilities early and drive candidate selection alongside our discovery, engineering, computational and virology teams.
You will also stay close enough to the bench to troubleshoot an SPR run, challenge an assay result or help a scientist work through an unexpected dataset.
This role is for a scientist who has worked inside a drug-discovery or product-development environment, understands why each experiment is being run, and is used to turning the results into programme decisions. If your background is mainly in academic core-facility or analytical service work, this role is unlikely to be the right fit.
Lab-based at our White City, London site. You will need to be on-site at least 3 days per week.
If you want to shape how a growing biotech decides which antibodies go towards the clinic, we would like to hear from you.